Key Highlights

  • Abbott Laboratories (NYSE:ABT) reported third-quarter GAAP diluted EPS of USD 0.53 on Wednesday, October 21, 2026, down from USD 0.94, while adjusted diluted EPS rose 9.2% to USD 1.42.
  • Specified items totalled USD 1.69 billion before tax: USD 841 million of intangible amortisation, double the prior year, about USD 670 million of legal settlements and USD 178 million of other net expenses.
  • Electrophysiology, which treats heart rhythm disorders, grew 15.5% on a comparable basis to USD 873 million, while Cancer Diagnostics, the former Exact Sciences, grew 13.8% to USD 968 million.
  • Adjusted EPS beat the consensus estimate of USD 1.41 by one cent, and Abbott gives no GAAP EPS guidance because it cannot reliably forecast certain reconciling items.

Two Earnings Figures for One Quarter

Abbott Laboratories (NYSE:ABT), a diversified healthcare group spanning medical devices, diagnostics, nutrition and branded generic drugs, reported third-quarter results at 7:30 a.m. ET on Wednesday, October 21, 2026. GAAP diluted EPS fell to USD 0.53 from USD 0.94, and GAAP net earnings fell to USD 920 million from USD 1.64 billion. Adjusted diluted EPS, which excludes specified items, rose 9.2% to USD 1.42, against the consensus estimate of USD 1.41. Net earnings excluding specified items rose 8.7% to USD 2.48 billion. Sales grew 14.5% to USD 13.01 billion, or 7.0% on a comparable basis. Amortisation of intangible assets reached USD 841 million, against USD 420 million a year earlier. The gap between the two net earnings figures was about USD 1.56 billion on simple arithmetic.

How Acquisition Accounting Splits the Numbers

For Abbott Laboratories (NYSE:ABT), about half of the gap is an accounting effect of buying businesses, and legal settlements of about USD 670 million account for most of the rest. When a company acquires another, it books the purchased technology and customer relationships as intangible assets and expenses them over several years as amortisation, which reduces GAAP profit without using cash. Cancer Diagnostics, the former Exact Sciences, contributed USD 968 million of sales with no reported prior-year comparison, which is consistent with the doubling in amortisation. Adjusted EPS strips out these items, so it tracks operating performance more closely. That performance was led by Electrophysiology, up 15.5% comparable, Established Pharmaceuticals in key emerging markets, up 10.9%, and Cancer Diagnostics, up 13.8%. US sales rose 28.0% reported but 7.9% comparable, showing how much reported growth came from the acquisition.

Risks and What to Watch

The first risk for Abbott Laboratories (NYSE:ABT) is that GAAP earnings stay well below adjusted figures while amortisation runs near USD 841 million a quarter, which matters for investors who value the company on reported profit. The second is uneven growth across the portfolio: Neuromodulation sales fell 1.1% comparable and Rapid and Molecular Diagnostics grew only 0.9%. The third is that the acquired business must keep growing to justify its cost, with Cancer Diagnostics at 13.8% comparable growth this quarter. Abbott offers no GAAP EPS guidance, so the reported path is harder to model. Investors should watch the USD 0.63 quarterly dividend payable on Monday, November 16, 2026 and fourth-quarter adjusted EPS against the USD 1.62 to USD 1.67 guide.

Where Things Stand

The answer is that Abbott Laboratories (NYSE:ABT) posted GAAP EPS of only USD 0.53 because amortisation, legal settlements and other specified items absorbed about USD 1.56 billion of net earnings. The operating business still grew adjusted EPS 9.2%, and comparable sales growth of 7.0% with a reaffirmed USD 5.50 to USD 5.55 adjusted EPS range supports that view. The next catalysts are the dividend payment on November 16 and fourth-quarter results against the USD 1.62 to USD 1.67 guide. Guidance is a company forecast, not a guarantee, and this is not investment advice.